Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has shared an announcement.
Circio Holding ASA announced promising interim results from its TG01 phase 1/2 clinical trial for multiple myeloma, demonstrating excellent safety and preliminary efficacy in inducing RAS-specific T-cell responses. This progress supports further clinical development, addressing a significant unmet medical need for RAS-mutant multiple myeloma, and highlights the potential of TG01 as a future treatment option.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for gene and cell therapies. The company has developed a unique circRNA platform, circVec, which enhances protein expression significantly compared to traditional mRNA systems. Circio is also advancing its immuno-oncology program, TG01, targeting RAS-mutated cancers through collaborations in Norway and the USA.
YTD Price Performance: -12.25%
Average Trading Volume: 1,342,581
Current Market Cap: NOK61.62M
For an in-depth examination of 0RIS stock, go to TipRanks’ Overview page.